Browse result page of CancerPDF Database
Please click on CancerPDF_ID for detailed information about peptide.
| CancerPDF_ID | Peptide seq | Protein Name | Fluid | Mass/Z | Profiling Technique | Cancer Type | Expression Regulation | PUBMED ID |
|---|---|---|---|---|---|---|---|---|
| CancerPDF_ID34 | NGFKSHALQLN | Complement C4 precursor | Serum | 1228.65 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID35 | NGFKSHALQLNNR | Complement C4 precursor | Serum | 1498.91 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID36 | NGFKSHALQLNNRQ | Complement C4 precursor | Serum | 1626.85 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID37 | NGFKSHALQLNNRQI | Complement C4 precursor | Serum | 1739.93 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID38 | NGFKSHALQLNNRQIR | Complement C4 precursor | Serum | 1895.99 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID39 | GLEEELQFSLGSKINV | Complement C4 precursor | Serum | 1762.87 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID40 | GLEEELQFSLGSKINVKVGGNS | Complement C4 precursor | Serum | 2305.2 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID41 | GLEEELQFSLGSKINVKVGGNSKGTL | Complement C4 precursor | Serum | 2704.13 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID42 | GLEEELQFSLGSKINVKVGGNSKGTLKVLR | Complement C4 precursor | Serum | 3200.52 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID43 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4 precursor | Serum | 2551.06 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID44 | TLEIPGNSDPNFIPDGDFNSYVR | Complement C4 precursor | Serum | 856.33 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID45 | PDGDFNSYVR | Complement C4 precursor | Serum | 585.23 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID874 | TLEIPGNSDPNMIPDGDFNSYV | Complement C4-B | Plasma | 1198.03 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID875 | TLEIPGNSDPNMIPDGDFNS | Complement C4-B | Plasma | 1066.97 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID876 | TLEIPGNSDPNMIPDGDFN | Complement C4-B | Plasma | 1023.45 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID877 | SDPNMIPDGDFNSYVR | Complement C4-B | Plasma | 913.9 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID878 | NGFKSHALQLNNRQI | Complement C4-B | Plasma | "870.46, 580.64" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID879 | NGFKSHALQLNN | Complement C4-B | Plasma | 671.84 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID880 | NGFKSHALQLN | Complement C4-B | Plasma | 614.82 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID881 | GFKSHALQLNNR | Complement C4-B | Plasma | 692.87 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID882 | SHALQLNNRQIR | Complement C4-B | Plasma | 725.4 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID883 | SHALQLNNRQI | Complement C4-B | Plasma | 647.35 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID884 | GLEEELQFSLGSKINVKVGGNS | Complement C4-B | Plasma | 769.07 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID885 | GLEEELQFSLGSKINV | Complement C4-B | Plasma | "881.96, 588.31" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID886 | GLEEELQFSLGSKI | Complement C4-B | Plasma | "775.41, 517.27" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID887 | GLEEELQFSLGSK | Complement C4-B | Plasma | "718.86, 479.57" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID888 | GLEEELQFSLGS | Complement C4-B | Plasma | 654.81 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID889 | LEEELQFSLGSK | Complement C4-B | Plasma | 690.35 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID890 | EEELQFSLGSKINV | Complement C4-B | Plasma | 796.91 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID891 | EELQFSLGSKINVK | Complement C4-B | Plasma | 796.43 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID892 | EELQFSLGSKINV | Complement C4-B | Plasma | 732.38 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID893 | EELQFSLGSKI | Complement C4-B | Plasma | 625.83 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID894 | EELQFSLGSK | Complement C4-B | Plasma | 569.28 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID895 | ELQFSLGSK | Complement C4-B | Plasma | 504.76 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID896 | DDPDAPLQPVTPLQLFEGR | Complement C4-B | Plasma | 1054.53 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID897 | DDPDAPLQPVTPLQLFEG | Complement C4-B | Plasma | 976.48 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID898 | DDPDAPLQPVTPLQL | Complement C4-B | Plasma | 809.91 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID899 | DDPDAPLQPVTPL | Complement C4-B | Plasma | 689.34 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID900 | DDPDAPLQPVTP | Complement C4-B | Plasma | 632.81 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID901 | DDPDAPLQPVTPLQLFEGRRN | Complement C4-B | Plasma | 793.4 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID902 | GLEEELQFSLGSKINVK | Complement C4-B | Plasma | 946.01 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID903 | SLGSKINVKVGGNS | Complement C4-B | Plasma | 680.38 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID904 | NGFKSHALQLNNRQIR | Complement C4-B | Plasma | 632.67 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID905 | NGFKSHALQLNNRQ | Complement C4-B | Plasma | 542.95 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID906 | NGFKSHALQLNNR | Complement C4-B | Plasma | 749.89 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID1898 | SHALQLNNR | Complement C4-B | Serum | 1051.55229 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1899 | SRDKGQAGLQ | Complement C4-B | Serum | 1058.54687 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1900 | NGFKSHALQLNNR | Complement C4-B | Serum | 1497.78006 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1901 | NGFKSHALQLNNRQIR | Complement C4-B | Serum | 1895.02381 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1902 | DDPDAPLQPVTPLQLFEGRRN | Complement C4-B | Serum | 2377.20262 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1903 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4-B | Serum | 2550.16967 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1904 | TLEIPGNSDPNMIPDGDFNSYV | Complement C4-B | Serum | 2394.06856 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1905 | TTNIQGINLLFSSR | Complement C4-B | Serum | 1562.84166 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1906 | DDPDAPLQPVTPLQLFEG | Complement C4-B | Serum | 1950.95747 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1907 | DDPDAPLQPVTPLQLFEGR | Complement C4-B | Serum | 2107.05858 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1908 | VTASDPLDTLGSEGALSPGGVASLLR | Complement C4-B | Serum | 2482.2915 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1909 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4-B | Serum | 2566.16458 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1910 | ALEILQEEDLIDEDDIPVR | Complement C4-B | Serum | 2224.11107 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1911 | VGGNSKGTLKVLR | Complement C4-B | Serum | 1327.79358 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1912 | RGHLFLQTDQPIYNPGQR | Complement C4-B | Serum | 2139.09737 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1913 | GRTLEIPGNSDPNMIPDGDFNSYV | Complement C4-B | Serum | 2607.19113 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1914 | GRTLEIPGNSDPNMIPDGDFNSYVR | Complement C4-B | Serum | 2763.29224 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1915 | QIRGLEEELQFSLGSKINVK | Complement C4-B | Serum | 2287.2536 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1916 | SHALQLNN | Complement C4-B | Serum | 895.45118 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1917 | NGFKSHALQLNNRQI | Complement C4-B | Serum | 1738.9227 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1918 | GLEEELQFSLGSK | Complement C4-B | Serum | 1435.71947 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1919 | SHALQLNNRQIR | Complement C4-B | Serum | 1448.79604 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1920 | GFKSHALQLNNRQI | Complement C4-B | Serum | 1624.87977 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1921 | NGFKSHALQLNNRQ | Complement C4-B | Serum | 1625.83864 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1922 | KKEVYMPSSIFQDDFVIPDISEPGTWK | Complement C4-B | Serum | 3155.55254 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID4199 | AHSPWLKDSLSRTTNIQGI | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4200 | AHSPWLKDSLSRTTNIQGI | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4631 | DLLGVAHNNLMAMAQET | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5062 | FVIPDISEPGTWKI | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5063 | FVIPDISEPGTWKI | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5334 | GVQLQDVPRGQVV | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID5335 | GVQLQDVPRGQVV | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6186 | MGLDGATYDLEGHPQYL | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6187 | MGLDGATYDLEGHPQYL | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6491 | QDDFVIPDISEPGTWKI | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6492 | QDDFVIPDISEPGTWKI | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6798 | SELQLSVSAGSPHPAIA | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6799 | SELQLSVSAGSPHPAIA | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6801 | SELQLSVSAGSPHPAIARLTV | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6802 | SELQLSVSAGSPHPAIARLTV | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6931 | SIFQDDFVIPDISEPGTWKI | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6932 | SIFQDDFVIPDISEPGTWKI | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6934 | SIFQDDFVIPDISEPGTWKISA | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6935 | SIFQDDFVIPDISEPGTWKISA | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7029 | SNWLLSQQQADGSF | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7030 | SNWLLSQQQADGSF | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7032 | SNWLLSQQQADGSFQDLSPV | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7033 | SNWLLSQQQADGSFQDLSPV | Complement component C4B (Childo blood group) 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7350 | TASDPLDTLGSEGALSPGGVASLL | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7351 | TASDPLDTLGSEGALSPGGVASLL | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7353 | TASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMI | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7354 | TASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMI | Complement component C4B (Childo blood group) 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7357 | TAYALTLTKAPADLRGV | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7468 | TLEIPGNSDPNMIPDGDFNSYVRV | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7469 | TLEIPGNSDPNMIPDGDFNSYVRV | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7501 | TLLSGFHALRADLEKLTSL | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7502 | TLLSGFHALRADLEKLTSL | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8041 | VVARGSFEFPVGDAV | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8042 | VVARGSFEFPVGDAV | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8296 | YLAPTLAASRY | Complement C4-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8297 | YLAPTLAASRY | Complement component C4B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID9453 | SHALQLNNR | Complement C4-A/Complement C4-B | Plasma | 1052.56 | MALDI-TOF | Colorectal cancer | "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " | 26379225 |
| CancerPDF_ID9458 | LQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1154.68 | MALDI-TOF | Colorectal cancer | "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " | 26379225 |
| CancerPDF_ID9460 | ALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1225.72 | MALDI-TOF | Colorectal cancer | "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " | 26379225 |
| CancerPDF_ID9466 | GLEEELQFSLGSK | Complement C4-A/Complement C4-B | Plasma | 1436.72 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
| CancerPDF_ID9467 | SHALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1449.77 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis group than adenoma and CRC groups | 26379225 |
| CancerPDF_ID9469 | NGFKSHALQLNNR | Complement C4-A/Complement C4-B | Plasma | 1499.79 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis group than adenoma and CRC groups | 26379225 |
| CancerPDF_ID9476 | GFKSHALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1782 | MALDI-TOF | Colorectal cancer | Higher intensity in liver metastasis than adenoma and CRC groups. | 26379225 |
| CancerPDF_ID9479 | GLEEELQFSLGSKINVK | Complement C4-A/Complement C4-B | Plasma | 1891.02 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9480 | NGFKSHALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1896.03 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9481 | NGFKSHALQLNNRQIR(NH4) | Complement C4-A/Complement C4-B | Plasma | 1913.01 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9492 | GLEEELQFSLGSKINVKVGGNSK | Complement C4-A/Complement C4-B | Plasma | 2433.3 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9617 | GLEEELQFS | Complement C4-B | Serum | 526.24 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9618 | GLEEELQFSLGSK | Complement C4-B | Serum | 718.84 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9619 | EEELQFSLGSKIN | Complement C4-B | Serum | 747.35 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9620 | EEELQFSLGSKINV | Complement C4-B | Serum | 796.89 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9621 | GLEEELQFSLGSKIN | Complement C4-B | Serum | 832.4 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9622 | NGFKSHALQLNNRQI | Complement C4-B | Serum | 580.64 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9623 | GLEEELQFSLGSKINV | Complement C4-B | Serum | 881.97 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9624 | PDAPLQPVTPLQLFEGR | Complement C4-B | Serum | 626.67 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9625 | GLEEELQFSLGSKINVK | Complement C4-B | Serum | 630.99 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9626 | DDPDAPLQPVTPLQLFEGR | Complement C4-B | Serum | 703.36 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9627 | GLEEELQFSLGSKINVKVGGNS | Complement C4-B | Serum | 769.05 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID11552 | HALQLNNRQ | Complement C4-B | Serum | 1092.5788 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID11553 | HALQLNNRQI | Complement C4-B | Serum | 1205.6629 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID11554 | HALQLNNRQIR | Complement C4-B | Serum | 1361.764 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID11945 | NGFKSHALQLNNRQ | Complement C4-B | Serum | 1625.8386 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID11946 | NGFKSHALQLNNRQI | Complement C4-B | Serum | 1738.9227 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID11947 | NGFKSHALQLNNRQIR | Complement C4-B | Serum | 1895.0238 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12189 | SHALQLNNRQ | Complement C4-B | Serum | 1179.6109 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12190 | SHALQLNNRQI | Complement C4-B | Serum | 1292.6949 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12191 | SHALQLNNRQIR | Complement C4-B | Serum | 1448.796 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
| CancerPDF_ID12440 | TLEIPGNSD | Complement C4-B | Serum | 944.44509 | LC-MS | Melanoma | "Present in 7 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |